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ABSTRACT
Bacteria have evolved a multitude of systems to pre-
vent invasion by bacteriophages and other mobile
genetic elements. Comparative genomics suggests
that genes encoding bacterial defence mechanisms
are often clustered in ‘defence islands’, providing a
concerted level of protection against a wider range of
attackers. However, there is a comparative paucity of
information on functional interplay between multiple
defence systems. Here, we have functionally char-
acterised a defence island from a multidrug resis-
tant plasmid of the emerging pathogen Escherichia
fergusonii. Using a suite of thirty environmentally-
isolated coliphages, we demonstrate multi-layered
and robust phage protection provided by a plasmid-
encoded defence island that expresses both a type
I BREX system and the novel GmrSD-family type
IV DNA modification-dependent restriction enzyme,
BrxU. We present the structure of BrxU to 2.12 Å, the
first structure of the GmrSD family of enzymes, and
show that BrxU can utilise all common nucleotides
and a wide selection of metals to cleave a range
of modified DNAs. Additionally, BrxU undergoes a
multi-step reaction cycle instigated by an unexpected
ATP-dependent shift from an intertwined dimer to
monomers. This direct evidence that bacterial de-
fence islands can mediate complementary layers of
phage protection enhances our understanding of
the ever-expanding nature of phage-bacterial inter-
actions.
INTRODUCTION
Bacteria are outnumbered 10-fold by the estimated ≥1030
phages on Earth (1,2), and are infected at a rate of 1025 per
second (3). This vast predator–prey interaction has driven
the evolution of varied means of protection (4–6). Examples
include the well-established restriction-modification (R-M)
(7), abortive infection (8) and CRISPR-Cas (9) systems.
R-M systems have previously been observed clustered in
‘immigration control regions’ (10), and functional stud-
ies examined the differential responses from multiple R-
M systems (11–13). Recent comparative genomic analy-
ses have revealed that diverse phage-resistance genes are
indeed commonly clustered into ‘defence islands’ (14,15).
By coupling this clustering phenomenon with ‘guilt-by-
association’ inference of function, many putative individ-
ual phage-resistance systems have been identified and char-
acterised (16). This has in part contributed to the ongo-
ing proliferation of studies focussing on individual sys-
tems including Bacteriophage Exclusion (BREX) (17), DIS-
ARM (18), BstA (19), prokaryotic Argonaute (20), bacte-
rial cGAS (21), and SspABCD (22), amongst others. Fur-
ther systematic studies are now needed that address the
functional interplay between these diverse phage-resistance
systems within defence islands.
One common pairing in identified defence islands (14,15)
is between genes encoding Phage Growth Limitation (Pgl)
systems (23) and GmrS/GmrD type IV restriction en-
zymes (24). Using the Pgl alkaline phosphatase gene, pglZ,
to locate phage-resistance genes, the distinct BREX sys-
tems were identified in 10% of bacterial and archaeal
genomes (17). BREX methyltransferases hemi-methylate
non-palindromic 6 bp sequences on the N6 adenine nitro-
gen (N6mA) at the fifth position of the motif (17,25,26).
This methylation marks host DNA, leaving incoming non-
methylated DNA susceptible to BREX attack. The mech-
anistic basis of the prevention of phage proliferation by
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BREX is unknown. Whilst BREX targets non-modified
DNA, type IV restriction enzymes such as GmrSD recog-
nise and cleave modified DNA such as that from phage
T4 (27). GmrS contains Domain of Unknown Function
(DUF) 262, which is proposed to be involved in nucleotide
hydrolysis (28). GmrD contains DUF1524, which is pro-
posed to be an HNH nuclease domain (28). Whilst GmrSD
systems were originally identified as being encoded by sepa-
rate gmrS and gmrD genes, the predominant form is a single
polypeptide produced from a gmrSD gene fusion (28–30).
These GmrSD fused polypeptides can also sometimes be
extended with a diverse array of additional DUF domains
(28).
Type IV restriction enzymes include multiple unre-
lated families, with varied architectures and mechanisms,
which provide specificity towards diverse DNA modifica-
tions (31). This includes 5-methyl cytosine (5mC) and 5-
hydroxymethyl cytosine (5hmC) that have been recently
identified in a widening range of eukaryotic systems, includ-
ing mammalian stem cells and nerve tissues (32–34). Type
IV enzymes are therefore being used to map epigenetic mod-
ifications, by allowing cleavage of targeted DNAs and anal-
ysis of the resulting fragments by next generation sequenc-
ing (35–37).
We have identified a phage defence island containing
BREX and a type IV restriction enzyme, encoded on a
multidrug resistant plasmid of the emerging animal and
human pathogen Escherichia fergusonii (38). The interplay
between individual phage-resistance systems encoded to-
gether within a phage defence island is not currently well
understood. Using a suite of 30 coliphages isolated during
undergraduate practical classes, we discovered that an atyp-
ically large BREX operon offers complementary protection
against a broad range of phages when associated with the
type IV GmrSD homologue, BrxU. Subsequent analyses of
BrxU have produced the first structures of the GmrSD fam-
ily, and provided biochemical insight into a complex reac-
tion cycle of DNA-modification dependent cleavage.
MATERIALS AND METHODS
Bacterial strains and culture conditions
Total genomic DNA (gDNA) of E. fergusonii ATCC 35469
was obtained from ATCC. Escherichia coli strains DH5
(ThermoFisher Scientific), BL21 (DE3) (ThermoFisher
Scientific), NEB2796 (New England Biolabs, NEB) and
ER2796 (39) were grown at 37◦C, either on agar plates or
shaking at 220 rpm for liquid cultures. Luria broth (LB)
was used as the standard growth media for liquid cul-
tures, and was supplemented with 0.35% (w/v) or 1.5%
(w/v) agar for semi-solid and solid agar plates, respec-
tively. Growth was monitored using a spectrophotometer
(WPA Biowave C08000) measuring optical density at 600
nm (OD600). When necessary, growth media was supple-
mental with ampicillin (Ap, 50 g/ml), kanamycin (Km,
50 g/ml), streptomycin (Sm, 100 g/ml), tetracycline (Tc,
10 g/ml), isopropyl--D-thiogalactopyranoside (IPTG, 1
mM), L-arabinose (L-ara, 0.1% w/v) or D-glucose (glu, 0.2%
w/v). For growth curves (Figure 1), single colonies were
used to inoculate overnight cultures of LB incubated at
37◦C. The overnight culture was used to inoculate 200 l of
LB at an OD600 of 0.01 in the corresponding well of a ster-
ile 96-well plate. Cultures were infected with phage stocks
to a Multiplicity of Infection MOI of 0.001. Plates were in-
cubated at 37◦C within a SPECTROstar Nano plate reader
(BMG Labtech) shaking at 400 rpm. OD600 was measured
at 10 min intervals and the mean average for each time point
was calculated from three biological repeats. Data shown
are mean values with standard deviation represented by er-
ror bars.
Isolation and use of environmental coliphages
All E. coli bacteriophages were isolated from freshwater
sources in Durham city centre and the surrounding areas.
Water sampling and the first round of phage isolation was
performed as an undergraduate laboratory practical session
at Durham University. A 10 ml water sample was filtered
through a 0.22 m filter to remove debris. Filtrates were
supplemented with 10 ml of LB, and then inoculated with 1
ml of an overnight culture of E. coli DH5. Cultures were
grown for 3 days before a 1 ml aliquot was transferred to a
sterile microcentrifuge tube and centrifuged at 12 000 × g
for 5 min at 4◦C. The supernatant was transferred to a new
microcentrifuge tube and 100 l of chloroform was added
to kill any remaining bacteria. Samples were vortexed be-
fore a serial dilution series was prepared in phage buffer
(10 mM Tris–HCl pH 7.4, 10 mM MgSO4, 0.1% gelatin).
10 l of serial dilutions and 200 l of E. coli DH5 were
added to 4 ml of semi-solid LB agar in a sterile 7 ml plas-
tic bijou. Samples were gently mixed and poured on to LB
agar plates. Plates were incubated overnight and individual
plaques were harvested the following morning using sterile
toothpicks into 200 l phage buffer. Serial dilutions were re-
prepared and a series of agar plates were poured as detailed
above. These steps were repeated as necessary to ensure a
single plaque morphology was observed for all dilutions.
Lysates were then prepared by scraping a confluent lawn of
phage plaques into a 50 ml centrifuge tube. 3 ml of phage
buffer and 500 l of chloroform was added before mixing
with a vortex for 2 min. Samples were incubated at 4◦C for
30 min before being centrifuged at 4000 x g for 20 min. The
supernatant was transferred to a sterile glass bijou and 100
l of chloroform was added. Phage lysates were stored at
4◦C. Efficiency Of Plating (EOP) values were calculated by
determining the phage titre on a test strain, divided by the
titre on a control strain. The EOP values obtained used E.
coli DH5 WT as control strain throughout, to allow direct
comparisons between the multiple plasmid backbones used
in test strains. EOP data were collected in triplicate and the
mean value is shown along with standard deviation.
DNA isolation and manipulation
Analysis of pEFER was performed using BLAST (40). Fur-
ther amino acid sequence alignments were performed us-
ing PROMALS3D (41). All oligonucleotide primers used
in this study (Supplementary Table S3) were obtained from
Integrated DNA Technologies. PCR amplicons and plas-
mids were purified using Monarch DNA kits (NEB). PCR,
restriction digests, ligations, transformations and agarose
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Φ pEFER pEFER-brxA::Tn5 pEFER-str::Tn5EOP ± SD EOP ± SD EOP ± SD
AL25 1.03 ± 0.23 0.90 ± 0.22 0.86 ± 0.39
Alma 0.73 ± 0.18 0.97 ± 0.03 0.96 ± 9.23 x10-2
Bam 5.75 x10-4 ± 5.19 x10-4 1.01 x10-3 ± 7.24 x10-4 1.50 x10-4 ± 7.89 x10-5
Baz 0.73 ± 0.58 1.40 ± 1.17 0.35 ± 0.16
BB1 0.48 ± 0.21 1.32 ± 0.7 0.62 ± 0.19
BGP 4.00 x10-2 ± 5.40 x10-2 0.14 ± 0.13 9.09 x10-2 ± 0.15 x10-9
BHP 1.21 ± 0.42 1.29 ± 0.50 1.34 ± 0.36
CP <1.36 x10-8 ± 4.72 x10-9 0.17 ± 0.17 1.36 x10-7 ± 1.72 x10-8
CS16 5.95 x10-8 ± 7.35 x10-8 2.73 x10-3 ± 9.56 x10-4 <8.26 x10-8 ± 9.85 x10-7
EH2 <3.44 x10-7 ± 1.06 x10-7 1.94 ± 1.36 <3.44 x10-7 ± 1.06 x10-7
EL <3.31 x10-8 ± 1.81 x10-8 0.18 ± 6.06 <3.31 x10-9 ± 1.81 x10-9
Geo <2.19 x10-8 ± 8.30 x10-9 4.96 x10-2 ± 3.95 x10-3 <2.19 x10-8 ± 8.30  x10-9
Jura 1.07 ± 0.45 1.22 ± 0.63 1.28 ± 0.54
Mak 2.43 x10-3 ± 3.17 x10-4 3.73 x10-3 ± 2.37 x10-3 7.0 x10-4 ± 3.98 x10-4
Mav <2.37 x10-8 ± 1.71 x10-8 3.43 x10-7 ± 3.97 x10-7 <2.05 x10-8 ± 1.37 x10-8
NP <4.11 x10-8 ± 8.09 x10-9 0.17 ± 8.37 x10-2 <4.11 x10-8 ± 8.09 x10-9
NR1 <3.26 x10-8 ± 1.73 x10-8 0.13 ± 8.76 x10-2 <3.20 x10-8 ± 1.73 x10-8
PATM <4.17 x10-8 ± 8.07 x10-9 1.06 ± 0.16 <3.08 x10-8 ± 2.13 x10-8
Pau <2.86 x10-8 ± 1.69 x10-8 1.19 ± 0.76 <2.87 x10-8 ± 1.70 x10-8
QOTSP 4.92 x10-7 ± 8.18 x10-7 0.10 ± 7.52 x10-2 <1.50 x10-8 ± 9.82 x10-9
SAP <7.95 x10-8 ± 2.44 x10-8 1.74 ± 0.13 <7.95 x10-8 ± 2.44 x10-8
Sipho 2.04 x10-3 ± 2.09 x10-3 3.12 ± 2.47 1.38 x10-4 ± 3.81 x10-5
Solly 4.21 x10-7 ± 2.37 x10-7 0.11 ± 9.91 x10-2 <8.51 x10-7 ± 3.46 x10-7
Some <1.40 x10-7 ± 3.32 x10-8 1.97 ± 1.62 <1.40 x10-7 ± 3.32 x10-8
SPSP 1.26 ± 0.72 1.07 ± 0.43 0.63 ± 0.56
TB34 1.21 ± 0.32 0.97 ± 0.13 0.87 ± 0.29
TB36 <1.69 x10-7 ± 1.02 x10-7 0.3 ± 0.17 <3.47 x10-8 ± 1.12 x10-8
TB37 9.73 x10-3 ± 6.30 x10-3 1.42 ± 0.36 1.41 x10-3 ± 3.20 x10-3
Titus 4.71 x10-3 ± 9.77 x10-4 3.00 x10-2 ± 1.30 x10-2 3.01 x10-3 ± 5.78 x10-4




0.1 > EOP ≥ 0.01
0.01 > EOP ≥ 0.001
0.001 > EOP ≥ 0.0001
0.0001 > EOP
Figure 1. Plasmid pEFER confers effective phage defence. (A) Plasmid map of Escherichia fergusonii ATCC 35469 pEFER, showing putative defence island
and antibiotic resistance genes. Transposon insertion sites are indicated for pEFER-brxA::Tn5 and pEFER-str::Tn5. BrxB and PglZ are in a different
reading frame from other genes in the defence island. (B–E), Growth curves of E. coli DH5 (black) and E. coli DH5 pEFER (red), infected with phages
or an uninfected control. Bacterial cultures were grown to mid exponential phase and diluted to a starting OD600 of 0.05. Cultures were inoculated at
an MOI of 0.001 at time point 0 min and absorbance was measured every 10 min. Experiments were run in triplicate and the mean values are plotted.
Error bars represent the standard deviation of replicates. (F) Efficiency Of Plating (EOP) values for E. coli DH5 strains containing pEFER or transposon
mutants of pEFER, pEFER-brxA::Tn5 and pEFER-str::Tn5, against a suite of environmentally isolated coliphages. The control strain was E. coli DH5
WT. Values are mean EOPs from triplicate data, shown with standard deviation. Values presented with < extended below the range of this assay and no
plaques were observed.
ular biology techniques. Constructed plasmids were con-
firmed via sequencing with an Abi 3370 DNA sequencer.
The pSAT1-LIC-brxU+ expression construct adds a cleav-
able N-terminal His6-SUMO tag, and was generated via
Ligation Independent Cloning (LIC). Primers TRB851
and TRB852 were used to amplify brxU from pEFER
for insertion into pSAT1-LIC (42) to produce pTRB446.
Primers TRB865 and TRB866 were used to amplify brxU
from pEFER which was inserted into pBAD30 to pro-
duce pBAD30-his6-brxU+. Golden Gate Assembly (GGA)
(43) was performed to produce pBrxXL and its deriva-
tives. QuikChange mutagenesis was performed to remove
BsaI sites from pUC19 (NEB) to produce pTRB479. The
pEFER BREX locus was partitioned into multiple ∼3–4
kb regions and amplified using primers with flanking BsaI
sites with unique overhang sequences (Supplementary Ta-
ble S3). pTRB479 and inserts were digested with BsaI and
ligated with T4 DNA ligase to create GGA donor con-
structs. A 3:1 insert: vector ratio was used in a GGA reac-
tion containing BsaI and T4 DNA ligase. Positive colonies
of transformed E. coli DH5 were selected for on LB
agar containing ampicillin. Transposon mutagenesis was
performed using EZ::Tn5TM < Kan-2 > according to the
manufacturer’s instructions (Cambridge Bioscience). Inser-
tion events were mapped using random-primed PCR (44)
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his6-brxU+ were designed and GenScript were commis-
sioned to generate the constructs. To produce syntheti-
cally modified substrates for BrxU (Figure 3B and Sup-
plementary Figure S3), PCR was performed using primers
TRB1434 and TRB1435 to produce a 2.7 kb amplicon with
pUC19 as a template, replacing dCTP when needed with
either 5mC or 5hmC (Jena Biosciences) to produce DNA
substrates containing the desired modification. Amplicons
were analysed by agarose gel electrophoresis and purified
using a Monarch DNA gel extraction kit (NEB). DNA
containing 5hmC was subsequently treated with either -
glucosyltransferase (NEB), using UDP-glucose as a donor,
to produce glc-5hmC DNA, or with T4 Polynucleotide Ki-
nase (NEB) and T4 DNA Ligase (NEB), to produce a circu-
larised form, prior to re-purification. Phage gDNA was iso-
lated via phenol-chloroform extraction and purified using
ethanol precipitation. Bacterial gDNA for PacBio sequenc-
ing was isolated using the Quick-DNA Miniprep Plus Kit
(Zymo Research).
Pacific biosciences sequencing
Libraries for sequencing were prepared using the SMRT-
bell Template Prep kit 1.0 (Pacific Biosciences). Briefly, pu-
rified bacterial gDNA was sheared using gTubes (Covaris)
to produce DNA fragments with a mean size of 5–10 kb.
The DNA was damage repaired, end repaired and ligated to
SMRT-bell adapters. Non SMRT-bell DNAs were removed
by exonuclease treatment. Sequencing was performed on ei-
ther a PacBio RSII or a Sequel I sequencer (Pacific Bio-
sciences). Data were analysed using PacBio SMRTAnalysis
2.3.0 Modification and Motif Analysis 1.0 for RSII data,
or SMRTLink 6.0 software Base Modification Analysis for
Sequel data, to identify DNA modifications and their cor-
responding target motifs.
Protein expression and purification
For expression of target proteins, E. coli BL21 (DE3) was
transformed with pSAT1-LIC or pBAD30 expression con-
structs. A single colony was used to inoculate 25 ml LB con-
taining Ap and grown overnight at 37◦C. Overnight cultures
were used to inoculate six 2 l baffled flasks containing 1 l
2× YT supplemented with Ap. Cultures were grown at 37◦C
shaking at 180 rpm until an OD600 of ∼0.6 at which point
protein expression was induced. For pSAT1-LIC-brxU+,
expression was induced by the addition of IPTG to a final
concentration of 1 mM and cultures were grown overnight
at 18◦C. For pBAD30-his6-brxU+, expression was induced
by the addition of L-ara to a final concentration of 0.1%
(w/v) and grown for 4 h at 37◦C. Selenomethionine (SM)-
labelled protein expression was performed using the SM
Medium expression kit (Molecular Dimensions). pSAT1-
LIC-brxU+ was used to transform E. coli BL21 (DE3) and
a single colony was used to inoculate a 5 ml SM Complete
Medium starter culture containing Ap, which was grown for
36 h at 37◦C. Starter cultures were used to inoculate 1 l of
SM Complete Medium in a 2 l baffled flask to an OD600
of 0.05 and cultures were grown at 37◦C until an OD600 of
0.6–0.8, at which point 10 ml of 100× methionine inhibitory
feedback mix (10 g/l lysine, phenylalanine, threonine and 5
g/l leucine, isoleucine, valine and L-SM) was added. 30 min
after the addition of inhibitory feedback mix, IPTG was
added to a final concentration of 1 mM to induce protein ex-
pression. Cultures were grown overnight at 18◦C. Cultures
were pelleted at 5000 × g for 30 min at 4◦C. Cell pellets were
resuspended in 50 ml of ice-cold A500 (20 mM Tris–HCl
pH 7.9, 500 mM NaCl, 10 mM imidazole and 10% glycerol)
and used immediately or flash frozen in liquid nitrogen and
stored at −80◦C.
Pellets were lysed via sonication and centrifuged at 45 000
× g at 4◦C for 30 min. All clarified cell lysates were passed
over a 5 ml HisTrap HP column (Cytiva), and washed with
50 ml of A500. His6-BrxU WT and mutants expressed from
pBAD30-his6-brxU+ were further washed with 50 ml of
W500 (20 mM Tris–HCl pH 7.9, 500 mM NaCl, 40 mM
imidazole and 10% glycerol) and eluted from the column
in B500 (20 mM Tris–HCl pH 7.9, 500 mM NaCl, 250
mM imidazole and 10% glycerol). Imidazole was removed
via dialysis and samples were stored in glycerol (30% w/v)
at −80◦C. His6-SUMO-BrxU expressed from pSAT1-LIC-
brxU+ was treated with hSENP2 SUMO protease and dial-
ysed overnight into A100 (20 mM Tris–HCl pH 7.9, 500
mM NaCl, 10 mM imidazole and 10% glycerol). The result-
ing untagged BrxU was loaded on to a second 5 ml HisTrap
HP column and the flowthrough was collected and loaded
on to a 5 ml HiTrap Q HP column (Cytiva). The Q HP col-
umn was transferred to an Äkta Pure (Cytiva) FPLC sys-
tem and BrxU was eluted from the column over a gradi-
ent from 100% A100 to 100% C1000 (20 mM Tris–HCl pH
7.9, 1000 mM NaCl, 10 mM imidazole and 10% glycerol).
Fractions were analysed via SDS-PAGE and peak fractions
were pooled before being resolved via size exclusion through
a Sephacryl S-300 HR gel filtration column in preparative
SEC buffer (20 mM Tris–HCl pH 7.9, 500 mM KCl and 10%
glycerol). Fractions were analysed via SDS-PAGE and peak
fractions were pooled. The pooled sample was dialysed into
Xtal buffer (20 mM Tris–HCl pH 7.9, 200 mM NaCl and 2.5
mM DTT). Untagged BrxU for crystallisation was used im-
mediately, untagged BrxU samples for biochemical analysis
were stored in glycerol (30%, w/v) at −80◦C.
DNA cleavage assays
2 l of 100 ng/l gDNA was added to a mixture of 2
l 10× DPMG buffer (200 mM Tris–HCl pH 7.5, 500
mM CH3COOK, 100 mM MgSO4), 2 l 10 mM ATP, 5
l of 2 M BrxU and 9 l of nuclease free water. Nu-
clease free water was used for negative controls in place
of ATP. For metal-dependency assays (Figure 3C), Mg2+
was excluded from the sample buffer and replaced with the
relevant cation. For nucleotide-dependency assays (Figure
3D, E), the nucleotide was substituted as required. Samples
were incubated at 37◦C for 30 min and reactions were termi-
nated by incubating at 75◦C for 10 min. Agarose gels were
resolved at 120 V for 45 min in 1× TAE buffer containing
0.5 g/ml EtBr. Gels were visualised with BioRad Image
Lab software. All experiments were run in triplicate with
replicates on individual gels, with a single gel shown for each
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Nucleotide hydrolysis assays
Nucleotide hydrolysis was determined by measuring the
concentration of released Pi, and assays were performed ac-
cording to the BIOMOL green (Enzo Life Sciences) proto-
col. A 96-well plate format was used and columns 1 and 2
were used for phosphate standard serial dilutions to allow
for calculation of experimental results. Experimental wells
were set up in 50 l total volumes. Each well contained 5 l
10× DPMG buffer, 5 l of 1 mM NTP and 5 l of 5 M
protein, made up to 50 l with MilliQ (MQ) water. 5 l was
added for each additional reagent (EDTA, DNA) in place
of equal volumes of MQ water. EDTA was used at a final
concentrations of 10 mM, and 100 ng of respective substrate
DNA was used. All experiments were incubated at 37◦C
for 30 min shaking at 400 rpm and reactions were termi-
nated by the addition of 100 l of BIOMOL green reagent
(Cambridge Bioscience) and immediately transferred to a
SPECTROstar plate reader. Plates were incubated at 30◦C
shaking at 400 rpm whilst the BIOMOL green reagent de-
veloped. Absorbance at 620 nm was measured after 30 min.
Data shown are mean values averaged from three technical
replicates with error bars representing standard deviation.
Analytical gel filtration
A Superdex 200 Increase GL 5/150 (Cytiva) was connected
to an ÄKTA Pure system (Cytiva) and equilibrated by run-
ning through 2 column volumes of filtered MQ water and 5
column volumes of analytical SEC buffer (20 mM Tris–HCl
pH 7.9 and 150 mM NaCl) at 0.175 ml/min. It was then
calibrated using standard calibration kits (Cytiva). The re-
sulting calibration curve was used to determine dimer and
monomer states of BrxU according to elution volume and
molecular weight (67.9 kDa for a BrxU monomer). A 50 l
sample was prepared containing 5 l of 5 M BrxU and 5
l of 10× DPMG buffer, and made up to 50 l with MQ
water. For samples without MgSO4, DPMG buffer was re-
placed by DPMG-buffer (200 mM Tris–HCl pH 7.5, 500
mM CH3COOK). 5 l of 10 mM nucleotide was used to
replace 5 l of MQ water in nucleotide-containing samples
(Figure 3G). For analysis of BrxU mutants, all samples were
prepared containing 5 l protein, 5 l 10× DPMG buffer
and either 5 l of 10 mM ATP or 5 l of MQ water, and
made up to a total volume of 50 l with MQ water (Fig-
ure 5D). These 50 l samples were incubated at 37◦C for
15 min and then loaded to overfill a 10 l loop via a 50 l
Hamilton syringe. Two column volumes of analytical sizing
buffer was run through the sample loop directly on to the
column at 0.175 ml/min. Absorbance at 280 nm was mea-
sured corresponding to the eluting protein signal. Experi-
ments were performed a total of three times and a single
dataset is shown as representative of the triplicate data.
Protein crystallisation
Native and SM-derivatised BrxU were concentrated to a
final 12 mg/ml in Xtal buffer with the addition of 5 mM
MgSO4 and 2 mM AMP-PnP, and crystallisation trials were
performed with commercially available screens (Molecu-
lar Dimensions). Using a Mosquito Xtal3 robot (SPT
Labtech), drops were set at 200:100 nl and 100:100 nl (pro-
tein : precipitant) ratios at 18◦C. Crystals were visible af-
ter 24 hours in Pact Premier G8 (0.2 M Na2SO4, 0.1 M
Bis–Tris propane pH 7.5 and 20% w/v PEG 3350). Opti-
mised crystal formation was observed when substituting 0.2
M Na2SO4 for 0.2 M (NH4)2SO4, resulting in crystals from
which both native and SM-derivatised data were obtained.
Crystals were harvested by mounting into nylon cryo-loops
and soaking in a drop of 2:1 ratio of reservoir liquid and
cryo solution (20 mM Tris–HCl pH 7.9, 150 mM NaCl, 2.5
mM DTT and 80% glycerol), then flash freezing in liquid
nitrogen.
X-ray data collection and structure determination
Diffraction data were collected at Diamond Light Source
(DLS) using beamlines I24 (native 2.12 Å and SM-
derivatised 2.70 Å data) and I04 (native 2.85 Å data) (Sup-
plementary Table S2). Two individual 360◦ datasets were
collected from a single native crystal and merged using
the DIALS pipeline in iSpyB (Diamond Light Source) to
obtain data at 2.12 Å. An additional 5 datasets were ob-
tained from a different, individual crystal and merged to
produce another native dataset at 2.85 Å. A total of 15
datasets were collected from 4 SM-derivatised BrxU crys-
tals at the selenium peak (0.9786 Å) and merged to produce
a dataset at 2.70 Å. Merged data were processed via XDS
(45) and spacegroups were corroborated using AIMLESS
from CCP4 (46). The crystal structure of SM-BrxU was
solved via SAD using the SHELX (47) suite in CCP4 (46).
The starting model was then built using BUCCANEER
(48) and REFMAC (49). The resulting model was then used
as a search model for molecular replacement by PHASER
(50), to solve both the native 2.12 and 2.85 Å structures. The
initial outputs from molecular replacement were again built
in BUCCANEER (48), then iteratively refined and re-built
using PHENIX (51) and COOT (52), respectively. The qual-
ity of the final model was assessed using PHENIX, COOT
and the wwPDB validation server. Structural figures were
generated using PyMol (Schrödinger).
RESULTS
Discovery of the pEFER phage defence island
The initial study into BREX used comparative genomics
to compile a list of type I BREX systems (17). We selected
the plasmid-borne type I BREX system from E. fergusonii
ATCC 35469 as a suitable candidate to investigate phage
defence islands (Figure 1A). The 55.15 kb pEFER plasmid
contains 58 ORFs, including an extended BREX locus, mul-
tiple antibiotic-resistance genes, a toxin-antitoxin system, a
partitioning system for plasmid replication, and a varied set
of transposases (Figure 1A and Supplementary Table S1).
The putative ∼18 kb BREX locus contains the canonical
brxA, brxB, brxC, pglX, pglZ and brxL genes, with three
additional upstream genes we have named brxR, brxS and
brxT (Figure 1A). BrxR is a WYL-domain predicted tran-
scriptional regulator, BrxS is a putative IS3 family trans-
posase and BrxT is a hypothetical protein of unknown
function. A further gene, brxU, not part of the canonical
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BrxU protein contains DUF262 and DUF1524 domains,
and shares 13% amino acid sequence identity with the single
polypeptide type IV restriction enzyme GmrSD (30) (Sup-
plementary Figure S1). The presence of the putative type
IV restriction enzyme BrxU within the BREX locus raised
the possibility that pEFER encodes a novel multifunctional
phage defence island.
To test for activity against phages, E. coli DH5 was
transformed with a total genomic DNA (gDNA) extrac-
tion from E. fergusonii ATCC 35469, taking advantage
of the pEFER-encoded tetracycline resistance for plasmid
selection. E. coli DH5 pEFER and E. coli DH5 wild
type (WT) were then grown in the presence of a range of
environmentally-isolated coliphages (Figure 1B–D). Plas-
mid pEFER provided resistance against phage Pau and
Trib (Figure 1B/C), but not phage Baz (Figure 1D). The
uninfected controls reached the same final OD600, though
E. coli DH5 pEFER lagged slightly behind WT (Figure
1E).
Phages Pau, Trib and Baz were part of a larger
suite of thirty environmental coliphages that were isolated
from the River Wear and other waterways around Durham,
UK, by undergraduates completing a final year microbi-
ology practical module in 2016 and 2017 (see Acknowl-
edgements). To quantify the level of phage defence, the Ef-
ficiency Of Plating (EOP) of all thirty phages was deter-
mined against E. coli DH5 pEFER, using E. coli DH5
WT as the control (Figure 1F). EOP is the relative number
of plaques that a phage stock is capable of producing on
a particular bacterial strain (53). Plasmid pEFER reduced
the EOP for 22 of the 30 phages (Figure 1F). The scale of ef-
fect varied, with the EOP for phages such as CP and Pau
reduced by > eight orders of magnitude on E. coli DH5
pEFER (resulting in zero plaques), whereas phages such as
BGP and Trib only had a 100-fold reduction (Figure 1F).
As expected, Baz did not exhibit a reduced EOP (Figure
1D/F).
To confirm that phage defence was defence island-
dependent, in vitro transposon mutagenesis was performed
on plasmid pEFER. The resulting transformants were
screened for a loss of phage defence using Pau. Transfor-
mants were also screened for streptomycin susceptibility, to
identify a second, isogenic, plasmid for comparison. The
identified mutants were sequenced by random-primed PCR
to map the insertion sites (44). Clone pEFER-brxA::Tn5
has a transposon insertion within brxA, and clone pEFER-
str::Tn5 carries a transposon insertion within strB (Fig-
ure 1A). The pEFER-brxA::Tn5 and pEFER-str::Tn5 plas-
mids were then tested for phage defence using the same suite
of phages (Figure 1F). The pEFER-brxA::Tn5 insertion ab-
lated phage defence activity against 17 of the 22 previously
susceptible phages, confirming that the putative defence is-
land did indeed provide phage defence (Figure 1F). As five
phages, Bam, CS16, Mak, Mav and Titus, still had
a reduced EOP with pEFER-brxA::Tn5, we inferred either
that the transposon insertion did not fully remove activ-
ity from BREX and BrxU, or another phage-resistance sys-
tem could be encoded elsewhere on pEFER. Interestingly,
the EOP of CS16 changed from an eight-log reduction on
E. coli DH5 pEFER, to a three-log reduction on E. coli
DH5 pEFER-brxA::Tn5, raising the possibility that mul-
tiple systems were targeting CS16 (Figure 1F). The iso-
genic control plasmid pEFER-str::Tn5 conferred the same
EOP profile as progenitor plasmid pEFER (Figure 1F).
Taken together, our data show that the BREX/BrxU phage
defence island of pEFER provides a highly effective level of
defence against a broad range of phages.
pEFER phage defence is mediated by both BREX and BrxU
To characterise the specific phage defence mechanisms,
the entire ∼18 kb pEFER phage defence island was sub-
cloned in sections, and then inserted into plasmid pGGA
by Golden Gate Assembly (GGA) (43), yielding plasmid
pBrxXL (Figure 2A). Plasmid pBrxXL provided the recip-
rocal activity of pEFER-brxA::Tn5 (Figures 1F and 2B),
reducing the EOP of 17 out of 30 phages to the same level as
plasmid pEFER, and also modulating the EOP of CS16.
Because pBrxXL encodes the defence island, we hypoth-
esised that the phage defence phenotype was dependent
on both a BREX mechanism and the putative type IV re-
striction enzyme BrxU. The function of BREX relies upon
the activity of the methyltransferase PglX, and so plasmids
were made that contained either a deletion of pglX, brxU, or
the double mutant ΔbrxUΔpglX (Figure 2A). The mutant
plasmids were then tested against the suite of coliphages,
which demonstrated that the phages fall into two classes,
one that was targeted by BrxU, and therefore had reduced
EOP only on pBrxXL-ΔpglX, and another that was tar-
geted by BREX and had a reduced EOP only on pBrxXL-
ΔbrxU (Figure 2B). The double pBrxXL-ΔbrxUΔpglX mu-
tant did not provide any protection against phage attack,
supporting our hypothesis that this defence island car-
ries two phage resistance mechanisms: the canonical PglX-
mediated BREX system, and a novel mechanism mediated
by BrxU (Figure 2B). Furthermore, as pBrxXL-ΔbrxU re-
duced the EOP of CS16 by three orders of magnitude,
compared to the eight orders of magnitude of protection
provided by pEFER (Figure 1F), and pEFER reduced
the EOP of four phages not targeted by pBrxXL (Bam,
Mak, Mav and Titus) (Figure 1F), we suspect that pE-
FER also encodes a third phage defence system outside
the BREX/BrxU phage defence island, which awaits future
characterisation.
PglX methyltransferases produce hemi-methylated DNA
by generating N6-methylated adenines (N6mA) at the fifth
position within 6-bp non-palindromic sequences of host
DNA (17). The Bacillus cereus PglX targets TAGGAG (17)
and the E. coli equivalent, BrxX, targets GGTAAG (25).
Pacific Biosciences (PacBio) sequencing of gDNA from E.
fergusonii ATCC 35469 identified N6mA modifications at
the fifth adenine of 1810/1812 (99.89%) of genome-wide
GCTAAT motifs, alongside modifications from Dam (54)
and four type I R-M systems (55). The GCTAAT modi-
fication was then observed in gDNA extracts from E. coli
DH5 pEFER (Figure 2C), along with Dam and EcoKI
(56) methylation sites. To eliminate all E. coli methyla-
tion from the analyses, subsequent PacBio sequencing was
performed using the methylation-deficient E. coli strain
ER2796 (39). This analysis identified a single modification
motif, GCTAAT N6mA, in E. coli ER2796 strains contain-
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EOP ± SD EOP ± SD EOP ± SD EOP ± SD
AL25 0.83 ± 0.45 0.22 ± 0.43 1.42 ± 0.34 0.88 ± 0.13
Alma 0.11 ± 0.32 1.33 ± 0.73 1.02 ± 0.58 1.70 ± 1.30
Bam 0.65 ± 0.73 1.02 ± 0.41 0.64 ± 0.92 1.18 ± 0.82
Baz 1.49 ± 0.12 2.01 ± 0.53 1.50 ± 0.31 1.92 ± 0.68
BB1 0.33 ± 0.74 1.12 ± 0.78 0.79 ± 0.51 1.72 ± 1.63
BGP 1.14 x10-2 ± 3.21 x10-2 5.32 x10-2 ± 7.29 x10-2 0.87 ± 0.90 1.79 ± 1.07
BHP 0.74 ± 0.34 2.01 ± 0.41 0.32 ± 0.48 2.11 ± 0.41
CP <6.00 x10-8 ± 3.87 x10-8 <4.92 x10-8 ± 6.15 x10-8 0.76 ± 0.80 3.45 ± 0.50
CS16 6.47 x10-3 ± 7.11 x10-3 1.73 ± 0.91 5.32 x10-3 ± 5.91 x10-3 1.45 ± 0.35
EH2 <2.46 x10-9 ± 4.44 x10-9 <1.67 x10-9 ± 1.01 x10-9 1.42 ± 0.95 5.30 ± 3.90
EL <1.58 x10-7 ± 3.1 x10-7 <4.26 x10-7 ± 3.30 x10-7 0.99 ± 1.01 0.81 ± 0.57
Geo <1.70 x10-7 ± 9.87 x10-7 <3.03 x10-7 ± 8.23x10-7 0.92 ± 0.23 0.73 ± 0.27
Jura 0.68 ± 0.55 0.63 ± 0.10 1.51 ± 0.65 1.14 ± 0.54
Mak 1.24 ± 0.88 0.98 ± 0.49 2.01 ± 1.10 1.91 ± 1.17
Mav 0.87 ± 0.49 0.63 ± 0.95 0.77 ± 0.37 0.68 ± 0.41
NP <1.07 x10-7 ± 7.12 x10-7 <1.07 x10-7 ± 7.48 x10-8 1.20 ± 0.66 1.32 ± 1.11
NR1 <2.24 x10-7 ± 4.3 x10-7 1.02 x10-7 ± 9.07 x10-8 1.32 ± 0.39 1.21 ± 0.79
PATM <7.76 x10-7 ± 7.91 x10-7 0.7 ± 0.42 <7.76 x10-7 ± 8.21 x10-7 1.29 ± 1.04
Pau <2.54 x10-7 ± 3.56 x10-7 1.53 ± 1.40 <2.54 x10-7 ± 1.4 x10-7 2.14 ± 1.30
QOTSP <8.33 x10-8 ± 5.42 x10-8 <8.33 x10-8 ± 7.53 x10-8 2.73 ± 0.64 0.91 ± 0.12
SAP <1.71 x10-7 ± 3.01 x10-7 <4.52 x10-7 ± 3.87 x10-7 1.10 ± 0.82 0.82 ± 0.25
Sipho 8.33 x10-3 ± 4.23 x10-3 0.58 ± 0.71 6.30 x10-3 ± 0.88 x10-2 2.08 ± 1.92
Solly <2.48 x10-7 ± 9.82 x10-8 <3.07 x10-7 ± 5.28 x10-7 0.73 ± 0.36 1.82 ± 0.27
Some <7.14 x10-7 ± 6.23 x10-7 <2.86 x10-8 ± 7.01x10-9 0.32 ± 0.81 3.86 ± 0.30
SPSP 1.21 ± 0.43 0.46 ± 0.22 1.51 ± 0.54 0.61 ± 0.11
TB34 1.9 ± 0.39 1.51 ± 0.60 0.51 ± 0.47 1.60 ± 0.34
TB36 <2.07 x10-8 ± 9.01 x10-9 <2.07 x10-8 ± 8.94 x10-8 2.04 ± 0.59 0.84 ± 0.16
TB37 8.99 x10-3 ± 0.22 x10-2 2.52 x10-2 ± 1.74 x10-2 1.43 ± 0.73 0.72 ± 0.26
Titus 1.58 ± 0.81 0.78 ± 0.43 2.61 ± 0.61 0.93 ± 0.10








6.17 x10-2 ± 5.40 x10-2
1.63 ± 0.58
<5.11 x10-2 ± 5.43 x10-8
1.03 ± 0.64
<4.02 x10-7 ± 3.42 x10-7
<3.43 x10-7 ± 1.09 x10-7




<2.98 x10-7 ± 1.74 x10-7
<7.82 x10-8 ± 0.61 x10-7
1.42 ± 0.80
1.61 ± 1.11
<9.62 x10-8 ± 8.10 x10-8
<2.15 x10-7 ± 2.51 x10-7
1.11 ± 0.50
<7.89 x10-7 ± 4.88 x10-8
<8.24 x10-8 ± 2.21 x10-8
1.32 ± 0.48
0.67 ± 0.43
<5.28 x10-8 ± 6.65 x10-8
2.44 x10-2 ± 3.43 x10-2
1.41 ± 0.62
1.85 ± 0.47
Figure 2. pEFER phage defence island encodes active BREX and BrxU systems. (A) Linear representation of phage defence island and subsequent mutant
constructs. (B) EOP values for phage defence island constructs in (A). (C) PacBio methylome sequencing outputs for E. coli DH5 pEFER and E. coli
ER2796 strains containing pBrxXL or mutant derivatives. (D) EOP values for pBAD30-his6-brxU+. Expression of BrxU was induced by the addition of
0.1% L-arabinose. Values are mean EOPs from triplicate data, shown with standard deviation. Values presented with < extended below the range of this
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Figure 3. BrxU is a promiscuous type IV restriction enzyme. (A) Cleavage of phage EH2, EL and Geo gDNA by untagged BrxU. The gDNAs of
phages with reduced EOP values in the presence of pBAD30-his6-brxU+ (Figure 2D) were cleaved by BrxU in vitro. The gDNA of BrxU-insensitive
phage CS16 was not cleaved. All lanes contain 500 nM BrxU and 10 mM MgSO4, with and without 1 mM ATP. All phage gDNAs were tested in this
manner (Supplementary Figure S2). (B) DNA cleavage assays show untagged BrxU degrades DNA containing 5mC, 5hmC and glc-5hmC. BrxU does
not degrade DNA that does not incorporate modified cytosines. All lanes contain 500 nM BrxU and 10 mM MgSO4, with and without 1 mM ATP. (C)
Metal-dependent cleavage of Geo gDNA by untagged BrxU. Metal concentration is shown in M, as a titration with 500 nM BrxU and 1 mM ATP. (D-E)
Nucleotide-dependent cleavage of Geo gDNA by BrxU. All lanes contain 500 nM BrxU and 10 mM MgSO4. Nucleotide concentration is shown above
each lane. Non-hydrolysable analogues ATP- -S (A ) and GTP- -S (G ) are shown as controls and cannot be utilised by BrxU for DNA cleavage. All gel
data (A-E) are representative of triplicate experiments and samples were resolved in 1% agarose TAE at 120 V for 45 min. (F) Nucleotide hydrolysis assays
with untagged BrxU. BGP gDNA was the default DNA substrate. Presented data are the mean and standard deviations from triplicate experiments, with
data points overlaid. (G) Analytical size exclusion analysis of untagged BrxU. 10 l samples of 500 nM BrxU and nucleotides at 1 mM, with and without
10 mM MgSO4, were resolved at 0.175 ml/min. Traces in red represent samples that do not contain MgSO4. Dashed traces in black represent samples that
were pre-incubated at 37◦C with 10 mM MgSO4 prior to loading. Traces are representative of triplicate data, and relative elution positions for the dimeric
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pBrxXL-ΔbrxUΔpglX (Figure 2C). Our findings show that
the pEFER-encoded phage defence island encodes a PglX-
dependent BREX system.
Surprisingly, Figure 2B showed that of the 18 phages
with reduced EOPs, only five were BREX-sensitive; CS16,
PATM, Pau, Sipho and Trib (though the scale of im-
pact remained an impressive seven orders of magnitude in
the cases of PATM and Pau). As the remaining 13 phages
with reduced EOPs appeared BrxU-sensitive (Figure 2B),
we chose to further characterise BrxU. First, to confirm
that BrxU alone is sufficient to provide phage defence, we
inserted a hexahistidine-tagged WT brxU gene (his6-brxU)
into a pBAD vector and once again tested it against our
suite of coliphages (Figure 2D). The EOP profile on E. coli
DH5 pBAD30-his6-brxU+ was the same as that on E. coli
DH5 pBrxXL-ΔpglX (Figure 2B, D), demonstrating that
BrxU was indeed sufficient for phage defence, and that the
tag had no impact on activity. Thus our phage defence is-
land carries two distinct phage resistance mechanisms, one
PglX-dependent and one mediated by BrxU.
BrxU is a promiscuous type IV restriction enzyme
Single polypeptide type IV restriction enzymes recognise
and degrade double-stranded DNAs containing modified
cytosines (30). To determine whether BrxU was a restric-
tion enzyme, we over-expressed, purified and incubated un-
tagged BrxU protein with extracted phage gDNAs and
magnesium, in the presence and absence of ATP (Figure
3A and Supplementary Figure S2). Genomic DNAs from
the BrxU-sensitive phages (Figure 2D) were degraded by
BrxU in an ATP-dependent manner (such as for EH2,
EL and Geo), whereas gDNAs from BrxU-insensitive
phages (such as CS16), were not degraded (Figure 3A and
Supplementary Figure S2).
As GmrSD homologues have been shown to cleave
DNAs containing modified cytosines (30), a range of mod-
ified 2.7 kb DNA substrates were generated using pUC19
as a template, to include either 5mC, 5hmC or glucosyl-
5-hydroxymethyl cytosine (glc-5hmC) modifications. These
were then tested against BrxU, which recognised and de-
graded DNA containing any of the three modifications in
an ATP-dependent manner, but did not degrade unmodi-
fied DNA (Figure 3B). BrxU cleavage produced a smear of
low molecular weight fragments, and no specific banding
pattern (Figure 3B). BrxU degraded both linear and circu-
lar modified DNA, consistent with an endonuclease activity
(Supplementary Figure S3).
As magnesium was required for the nucleolytic activity
of BrxU (Figure 3A/B), nine divalent cations were titrated
to examine the metal-dependence of BrxU (Figure 3C).
Geo gDNA was cleaved in the presence of Mg2+ and
Mn2+ at ≥10–4 M, followed by both Fe2+ and Fe3+ al-
lowing cleavage at ≥10–3 M, and Co2+ and Ni2+ at ≥10–2
M (Figure 3C). Ca2+, Cu2+ and Zn2+ did not support
BrxU-dependent DNA cleavage (Figure 3C). As ATP was
a required co-factor, a range of nucleotides were tested
to examine co-factor promiscuity within BrxU. All the
nucleotides (ATP, GTP, CTP, TTP and UTP) supported
BrxU-dependent DNA cleavage of Geo gDNA, with ATP
as preferred nucleotide (Figure 3D). Non-hydrolysable ana-
logues ATP- -S and GTP- -S prevented nucleolytic ac-
tivity, and higher concentrations of GTP and CTP inhib-
ited BrxU (Figure 3D). As per other GmrSD homologues
(30), deoxynucleotides were also tested and all deoxynu-
cleotides supported BrxU-mediated DNA cleavage (Fig-
ure 3E). Deoxynucleotide-dependent activity occurred in a
concentration-dependent manner that did not show inhi-
bition at higher concentrations, as seen for GTP and CTP
(Figure 3D, E).
Next we aimed to determine whether the required nu-
cleotides were indeed hydrolysed by BrxU and whether hy-
drolysis altered in the presence of substrate DNAs. Nu-
cleotide hydrolysis was monitored by detection of released
inorganic phosphate (Pi), using BrxU-susceptible BGP
gDNA as substrate unless stated otherwise (Figure 3F). All
nucleotides and deoxynucleotides were hydrolysed by BrxU,
generating greater levels of Pi than the no nucleotide and
non-hydrolysable nucleotide controls (Figure 3F). Gener-
ated Pi levels were greater for the nucleotide than corre-
sponding deoxynucleotide co-factors, adenine and thymine
were the preferred bases for both the nucleotide and de-
oxynucleotide sets, and ATP was the clear preferred sub-
strate (Figure 3F). Pi production remained high in the ab-
sence of DNA and was not stimulated in the presence of un-
modified (Lambda) or another modified (Geo) gDNA; Pi
production was also reduced in the absence of magnesium,
or by the addition of EDTA (Figure 3F).
We then performed analytical size exclusion chromatog-
raphy (SEC) to examine potential conformational changes
within BrxU in the presence of nucleotides, with or with-
out magnesium (Figure 3G). Without nucleotide or metal
co-factors, BrxU eluted at a volume that indicated it is a
dimer in solution (Figure 3G). When ATP was added, but
not magnesium, BrxU eluted as a monomer, suggesting
dissociation upon nucleotide binding (Figure 3G). Magne-
sium alone did not cause dissociation (Figure 3G). In con-
trast to ATP, which caused magnesium-independent disso-
ciation of BrxU, all other nucleotides and deoxynucleotides
only induced BrxU dissociation when co-incubated with
magnesium, and the dissociation was often not complete
(Figure 3G). The non-hydrolysable ATP and GTP ana-
logues behaved in the same way as the hydrolysable coun-
terparts, with ATP- -S inducing magnesium-independent
dissociation, and GTP- -S requiring magnesium to do
the same (Figure 3G). Finally, whilst AMP could not in-
duce dissociation either with or without magnesium, ADP
caused magnesium-dependent dissociation, suggesting the
-phosphate is needed for dissociation, as well as the spe-
cific base interactions (Figure 3G).
Here, we have shown that BrxU is a promiscuous en-
zyme that uses a range of nucleotide and metal co-factors
to recognise and cleave DNA that contains any of at
least three different modifications, and this activity is de-
pendent on the initial nucleotide-driven dissociation of
BrxU dimers, and subsequent nucleotide hydrolysis. The
ability of BrxU to target modified phage DNA provides
a neat complement to BREX-mediated phage resistance,
which will target non-modified phage DNA (25). Together,
BrxU and BREX comprise a phage defence island that
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BrxU forms an interlocked dimer
In order to better understand the biochemical data, the
dimeric structure of BrxU was solved to 2.12 Å (Figure
4A and Supplementary Table S2). The N-terminal DUF262
domain of BrxU is connected to the C-terminal DUF1524
domain by a flexible linker. These linkers entwine in the ob-
served dimer, and then a loop from each N-terminal domain
connects with the corresponding protomeric C-terminal do-
main (bridged by a glycerol molecule in the structure), such
that the dimer is, in effect, two interlocked circles. The rel-
ative rotation between N- and C-terminal domains is easily
observed from a top-down view (Figure 4A), and generates
a cleft that runs diagonally across the dimer. This cleft is
∼21 Å wide, and surface electrostatics show clear patches of
electropositivity throughout, with the N-terminal domains
as the floor and the C-terminal domains forming the walls
(Figure 4B).
Bioinformatic analyses of GmrSD homologues identi-
fied RLFDS and DGQQR motifs related to nucleotide
binding and hydrolysis, respectively, within the N-terminal
DUF262 domains, and a DHIYP motif as part of a con-
served HNH nuclease within the C-terminal DUF1524 do-
mains (28). Previous structural modelling suggested that the
 -phosphate of a nucleotide substrate would be positioned
by the equivalent of BrxU D98, Q100, Q101 and R102 (28).
Within our structure, the position of the  -phosphate has
been taken by a sulphate ion that is bound by R102, and
nucleotide binding has been prevented by proximity of an
-helix and linker from the opposing protomer that fill the
corresponding space where a nucleotide might bind, also
blocking S42 of the RLFDS motif (Figure 4C). These en-
twined linkers between the N- and C-terminal domains are
shown with electron density from a 2Fo – Fc map con-
toured to 1.0 (Figure 4C). Our new understanding of the
BrxU dimers raises the possibility of a link between nu-
cleotide binding and dimer dissociation at a structural level,
wherein the nucleotide displaces the other protomer and
promotes disentanglement of the linker regions, to generate
monomers prior to nucleotide hydrolysis.
Within the C-terminal DUF1524 domain, D474 and
H475 of the BrxU DHIYP nuclease motif are positioned on
the surface of the DUF1524 domain to form part of the cleft
wall within BrxU (Figure 4D). A glycerol molecule bridges
the DUF1524 with a loop extending from the DUF262 do-
main, and an additional sulphate ion and chloride ion were
observed bound by looped regions of DUF1524 (Figure
4D). Despite setting crystals in the presence of AMP-PnP,
no nucleotide ligand was detected in the structure. The hy-
pothesis had been that AMP-PnP would stabilise a shift
from BrxU dimers to the monomeric form, to aid crystalli-
sation. Upon subsequent analytical SEC analysis, however,
we observed that whilst ATP and ATP- -S caused a con-
certed shift to monomers (Figure 3G), AMP-PnP unexpect-
edly did not (Supplementary Figure S4). It therefore makes
sense that our crystals contain BrxU dimers, without bound
nucleotide. Using ATP- -S in future studies may yield a
nucleotide-bound monomeric structure.
Whilst using the first BrxU structure to analyse datasets
from a range of BrxU crystals, a second dimeric structure
with a differing conformation of BrxU was solved, this time
to 2.85 Å (Figure 4E and Supplementary Table S2). Our
models described above for DNA-binding and dimer dis-
sociation rely upon a great deal of flexibility. By aligning
the two solved structures, domain movements were visu-
alised within the BrxU dimer (Figure 4E). The overall align-
ment provides an RMSD of 3.85 Å, indicating a poor aver-
age superposition (Figure 4E). By aligning the lower res-
olution structure through one C-terminal domain of the
higher resolution protomer, (which as independent domains
aligned well at 0.58 Å), distinct relative movements of each
of the other domains of the lower resolution structure can
be observed (Figure 4E). In this manner, we can see a 10 Å
movement of the protomeric N-terminal domain, and cor-
responding shifts of 12 and 26 Å for the N-terminal and C-
terminal domains of the second protomer, respectively (Fig-
ure 4E). This level of movement confirms the flexibility of
the BrxU dimer, and gives rise to an hypothesis that the 21 Å
cleft might widen to accommodate a substrate DNA, with
backbone phosphates supported by loops of the DUF1524
domain, as was seen for the observed sulphate and chloride
ions (Figure 4D).
BrxU-mediated phage resistance requires a multi-step pro-
cess
To generate structure-function information, we mutated
key residues in BrxU. Based on the alignment with
Eco94GmrSD (Supplementary Figure S1), our structural
information (Figure 4) and past bioinformatic studies (28),
we generated 11 single point mutants and one double mu-
tant of BrxU. To optimise over-expression and purification,
mutants were made in pBAD30-his6-brxU+.
Following the generation of the BrxU mutant constructs,
they were first tested for functionality in EOP assays (Fig-
ure 5A). The double mutant R38A/S42D and the single
mutants S42A, S42D, Q101A, R102A, D474A and H475A
were no longer phage-resistant, as the BrxU-dependent im-
pact on phage EOPs was ablated (Figure 5A). In contrast,
mutants N519A and E528A remained phage-resistant, al-
though the impact on EOP had been reduced to less than
a 10-fold change (Figure 5A). Mutants Q35A, R38A and
N485A were as functionally phage-resistant as WT BrxU
(Figure 5A).
The WT and mutant BrxU constructs where then used
to over-express and purify pure proteins (Supplementary
Figure S5A), which were tested for the ability to degrade
Geo gDNA (Figure 5B). The His6-BrxU WT protein de-
graded DNA as well as the untagged BrxU control (Figure
5B). Consistent with the EOP phenotypes, the double mu-
tant R38A/S42D and single mutants S42A, S42D, Q101A,
R102A, D474A and H475A lacked enzymatic activity and
did not digest the DNA (Figure 5B). Also consistently, mu-
tants Q35A, R38A and N485A digested the DNA as per
WT (Figure 5B). Surprisingly, whilst mutants N519A and
E528A had a minimal ability to restrict in vivo as shown by
EOP (Figure 5A), both mutant proteins readily degraded
the DNA substrate in vitro (Figure 5B).
The ability of the BrxU mutants to mediate nucleotide
hydrolysis was then determined in the presence of ATP and
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Figure 4. BrxU forms an intertwined dimer. (A) Cartoon overview of the BrxU dimer, shown as orthogonal views. Each protomer in the dimer is coloured
either in shades of cyan or pink, with differing colours for domains and linkers as indicated. Numbers show amino acid positions. Chloride ions are
represented as green spheres, sulphate ions are represented as sticks, and glycerol molecules are represented as sticks with white carbon backbones. (B)
Electrostatic surface potential shows patches of blue electropositivity throughout the surface of a cleft running diagonally across the BrxU dimer. (C) Solid
boxed region of (A), containing the proposed nucleotide binding site occupied by a sulphate ion and an -helix and linker from the opposing protomer.
The linker regions are shown with a 2Fo – Fc electron density map contoured to 1.0, which demonstrates the intertwined nature of dimerisation. Selected
amino acids within the RLFDS and DGQQR motifs are shown as sticks. (D) Dashed boxed region of (A), close-up of the DHIYP motif region within the
DUF1524 HNH nuclease C-terminal domain of the first protomer. An extended loop from the N-terminal domain of this protomer can be seen bridging
to the C-terminal domain through a glycerol molecule. (E) Overlay of the BrxU dimer with a second BrxU dimer structure solved to 2.85 Å, coloured in
light grey, shows inherent flexibility in domain position. The alignment was performed through the C-terminal domain of the first protomer (teal), to allow
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Mutant EOP ± SD
WT <4.85 x10-8 ± 2.43 x10-8
Q35A <5.94 x10-8 ± 1.71 x10-8
R38A <3.97 x10-8 ± 8.12 x10-8
R38A/S42D 0.89 ± 0.23
S42A 1.08 ± 0.43
S42D 1.19 ± 0.62
Q101A 0.95 ± 0.21
R102A 0.67 ± 0.47
D474A 0.72 ± 0.19
H475A 0.97 ± 0.11
N485A <3.97 x10-8 ± 6.12 x10-8
N519A 0.36 ± 0.63
E528A 0.13 ± 0.67
D
EOP ≥ 0.5














Figure 5. Analysis of BrxU mutants shows a complex reaction cycle. (A) EOP values for His6-BrxU and mutants against phage Geo. Values are mean EOPs
from triplicate data, shown with standard deviation. Values presented with < extended below the range of this assay and no plaques were observed. (B) DNA
cleavage assays with His6-BrxU WT and mutants. Geo gDNA was incubated with a gradient of BrxU concentrations at 37◦C for 60 min, in the presence of
10 mM MgSO4 and 1 mM ATP, and resolved via agarose gel electrophoresis at 120 V for 45 min. Control sample is untagged BrxU expressed from pSAT1-
LIC-brxU+. WT and mutants are expressed from pBAD30-his6-brxU+ and its derivatives. Data shown are representative of triplicate experiments. (C)
Hydrolysis of ATP by His6-BrxU WT and mutants. Control sample is untagged BrxU expressed from pSAT1-LIC-brxU+. WT and mutants are expressed
from pBAD30-his6-brxU+ and its derivatives. Presented data are the mean and standard deviations from triplicate experiments, with data points overlaid.
(D) Analytical size exclusion analysis of His6-BrxU WT and mutants. 10 l samples of 500 nM BrxU and 10 mM MgSO4, with and without 1 mM ATP,
were resolved at 0.175 ml/min. Control sample is untagged BrxU expressed from pSAT1-LIC-brxU+. WT and mutants are expressed from pBAD30-his6-
brxU+ and its derivatives. Traces in red represent samples that contained 0 mM ATP. Dashed traces in black represent samples that were pre-incubated at
37◦C with 1 mM ATP prior to loading. Traces are representative of triplicate data, and relative elution volumes for the dimeric and monomeric forms of
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similarly to the untagged BrxU control (Figure 5C). Non-
phage-resistant mutants S42D, R38A/S42D, Q101A and
R102A all showed reduced production of Pi. Unexpect-
edly, whilst mutant S42A was non-phage-resistant by EOP
(Figure 5A), and no longer digested DNA in vitro (Fig-
ure 5B), the level of Pi production was increased nearly 2-
fold over WT (Figure 5C). Phage-resistant mutants Q35A,
R38A, and N485A had approximately the same Pi produc-
tion levels as WT (Figure 5C). Weakly-phage-resistant mu-
tants N519A and E528A also showed similar Pi produc-
tion levels as WT (Figure 5C). Finally, mutants D474A and
H475A, part of the DHIYP motif in the C-terminal domain
(Figure 4D), were both non-phage-resistant by EOP (Fig-
ure 5A) and unable to digest DNA (Figure 5B), but showed
WT levels of Pi production (Figure 5C). This demonstrates
that nucleotide hydrolysis can occur independently within
the N-terminal domain, whilst DNA cleavage activity is as-
sociated with the C-terminal domain.
Our findings reveal that nucleotide binding and hydroly-
sis must occur before BrxU-mediated DNA cleavage, as Pi
production by the N-terminal nucleotide hydrolysis domain
was seen in the absence of a functional C-terminal nuclease
domain, but no DNA cleavage occurred without functional
nucleotide binding and hydrolysis. We speculate that nu-
cleotide binding leads to BrxU dissociation, and that subse-
quent hydrolysis allows re-association of BrxU monomers,
potentially concomitantly with binding to substrate DNA,
followed by cleavage. If this were the case, rounds of disso-
ciation and re-association would allow BrxU to rapidly hop
on and off the DNA substrate.
As BrxU dissociation is likely required for phage resis-
tance, we wanted to understand how the mutations im-
pacted the ability of BrxU to shift from dimer to monomer.
The mutant BrxU proteins were therefore examined by an-
alytical SEC in the presence of magnesium, with or with-
out ATP (Figure 5D). The His6-BrxU WT protein shifted
from dimer to monomer form in the presence of ATP, as ob-
served for the untagged BrxU control (Figure 5D). All mu-
tations in the C-terminal domain (D474A, H475A, N485A,
N519A and E528A) behaved similarly to WT (Figure 5D).
Phage-resistant mutants Q35A and R38A also behaved as
WT (Figure 5D).
Non-phage-resistant mutant Q101A was equally dis-
tributed between dimeric and monomeric forms prior to ad-
dition of ATP, and both Q101A and R102A dissociated in
the presence of ATP, indicating nucleotide binding (Figure
5D). As these mutants could clearly bind but not then hy-
drolyse the nucleotide (Figure 5C), this both fits their sug-
gested role in positioning the  -phosphate (Figure 4C), and
indicates that nucleotide binding is sufficient for dissocia-
tion. Double mutant R38A/S42D and single mutant S42D
did not dissociate in the presence of ATP, which explains
their lack of phage resistance (Figure 5A/D). Finally, non-
phage-resistant mutant S42A formed monomers even in the
absence of ATP (Figure 5D). The varied phenotypes of each
mutant were summarised to provide an overview (Supple-
mentary Figure S5B).
S42 lies within the dimerisation interface (Figure 4C)
and is clearly vital for mediating the switch from dimer to
monomer. S42A being permanently locked as a monomer
would explain the increased rate of nucleotide hydrolysis
leading to higher Pi production (Figure 5C). The fact that
the S42A monomeric mutant is non-phage-resistant further
demonstrates that nucleotide binding and hydrolysis is not
sufficient for DNA cleavage, but that there must be rounds
of both dissociation and re-association for BrxU-mediated
DNA cleavage to occur. These data indicate that a complex
cycle of events occurs to control the phage-resistance activ-
ity of BrxU (Supplementary Figure S6), as part of the wider
phage defence provided by pEFER.
DISCUSSION
Plasmid pEFER encodes a defence island that uses at least
two complementary systems to protect bacteria from phage
attack, one recognising specific non-modified sequence mo-
tifs within injected phage DNA (BREX), and a second
recognising DNA with specific modifications (BrxU) (Fig-
ure 6). As DNA modifications prevent BREX activity (25),
phages that have evolved to have modifications avoid tar-
geting by BREX, but then can become susceptible to BrxU
(Figure 6). This ‘belt and braces’ approach ensures better
protection for the bacterial host.
Whilst pEFER carries a type I BREX system (17), the
core genes are preceded by non-canonical upstream genes
brxS, brxT and brxR (Figure 1A). Of particular interest,
BrxR contains a WYL domain, which has been associ-
ated with a wide range of phage-resistance mechanisms as a
likely ligand-dependent transcriptional regulator (57). The
function of these additional genes is currently unclear and
remains to be determined through systematic deletion, tests
against our suite of phages and examination of DNA mod-
ification through PacBio sequencing. This will help to iden-
tify the minimal requirement for phage defence. The pE-
FER BREX provided protection against five of the tested
phages (Figure 2B). Of course, the BrxU-sensitive phages
might have the pre-requisite GCTAAT sequences in or-
der to be targeted by BREX, but the DNA modifications
making them BrxU-sensitive would prevent BREX activ-
ity (25). It will be interesting to sequence the genomes of
all our phages in due course, to identify GCTAAT motifs.
Any phage that has GCTAAT motifs, but is both BREX-
resistant by EOP assay, and is resistant to in vitro digestion
by BrxU, would by definition encode a BREX inhibitor, as
recently demonstrated for Ocr from phage T7 (58). Thirteen
phages were BrxU-sensitive. Inhibition of the BrxU homo-
logue GmrSD was observed with IPI*, a protein co-injected
with T4 DNA (29,30,59). If a similar inhibitor was used by
any of our phages, this would have been identified by the
phage having a high EOP value (Figure 2D) but then hav-
ing gDNA digested during in vitro BrxU assays (Figure 3A
and Supplementary Figure S2). Such a comparison did not
identify any likely candidates with a BrxU inhibitor within
our phage suite.
BrxU is a fused form of the bipartite GmrS/GmrD type
IV restriction system (24,29). Previous characterisation of
the fused homologue Eco94GmrSD showed an ability to
cleave glc-5hmC and 5hmC modified DNAs, using Mg2+
or Mn2+, and a limited set of nucleotides (30). In con-
trast, BrxU can utilise a much wider wide range of metal
and nucleotide co-factors, and cleaves DNA containing one
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Figure 6. Encoding multiple phage defence systems as a defence island manifests a complementary bacterial immune system capable of suppressing multiple
phage types. Phage genomes that contain modified cytosines are hydrolysed by BrxU. BREX effector proteins recognise unmethylated non-palindromic
BREX motifs in phage gDNA and prevent phage propagation. Methylation of this motif on host DNA by PglX protects the host from BREX effectors.
5hmC (Figure 3). As BrxU has been shown to hydrolyse
a wide range of nucleotides in vitro (Figure 3F) it might
be expected to be toxic due to depletion of the cellular nu-
cleotide pool. This has previously been considered for type
I R-M systems, and comparing the overall cellular ATP
turnover rates to the effect of these enzymes operating at
maximum indicated they would use up only 0.2% of the
available ATP (60). Accordingly, we have not observed tox-
icity from BrxU even when over-expressed. Nevertheless it
would still be of interest to examine the kinetics of BrxU-
dependent nucleotide turnover and whether it is coupled to
DNA binding and cleavage. The full range of DNA modifi-
cations recognised by BrxU also remains to be investigated,
and it is worth noting that strains containing the pEFER
defence island have the N6mA BREX modifications with-
out impact from BrxU, suggesting BrxU does not recognise
N6mA. As per other type IV restriction enzymes (61), it is
also likely that there will be a specific sequence motif re-
quired for BrxU cleavage as a result of recognising modifi-
cations. Further functional and structural information will
be needed to understand the basis of BrxU modification
recognition and sequence preference. The unrelated type IV
enzyme AbaSI uses an SRA-domain to recognise modified
DNA substrates in a conserved pocket (61), but no such ob-
vious pocket was observed for BrxU (Figure 4).
Strikingly, we have shown that nucleotide binding un-
expectedly shifts BrxU dimers towards a monomeric state
(Figure 3). Our BrxU structures are the first for the
GmrSD family, providing the highest resolution detail for
the widespread DUF262 and DUF1524 domains (28) (Fig-
ure 4). The structures reveal how nucleotide binding is
blocked in the dimer form (Figure 4C) and reveals inherent
flexibility that would allow for cycles of dimer separation
(Figure 4E). Further functional and structural characteri-
sation of BrxU monomers and dimers binding to co-factors
and DNA substrates will be needed to illuminate multiple
aspects of BrxU biochemistry. These will build on structural
and mutagenesis studies that have identified specific steps
of a complex reaction cycle that so far includes nucleotide
binding, monomerisation, nucleotide hydrolysis, dimerisa-
tion (perhaps in concert with modified DNA recognition),
and DNA cleavage (Supplementary Figure S6). Further
study will show how BrxU might transfer between cleavage
sites, and how it is possible for BrxU to be so promiscuous.
These types of developments will lead to a better theoretical
appreciation of how biological systems are able to utilise a
range of nucleotides, and to the design of selective reagents
to simplify the mapping of epigenetic DNA modifications.
Plasmid pEFER provides the host with antibiotic-
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advantageous in a dynamic environment. Our investigation
of how this multidrug-resistant plasmid protects its bac-
terial host from phage infection has highlighted the inter-
play of multiple complementary phage-resistance systems
encoded by a defence island on the plasmid. The recently
discovered prevalence of defence islands (14,15) may well
lead to the discovery of even more diverse and complex
interplays of defensive systems. It is likely that these will
be thwarted by counter-defence islands, as seen for anti-
CRISPRs (62,63). The biochemical characterisation of re-
ciprocal islands could expand our phage-derived arsenal of
biotechnological tools even further.
DATA AVAILABILITY
The crystal structures of BrxU have been deposited in the
Protein Data Bank under accession numbers 7P9K (native
2.12 Å structure) and 7P9M (native 2.85 Å structure). All
other data needed to evaluate the conclusions in the paper
are present in the paper and/or Supplementary Data.
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